Trial · NCT07914088
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The change of IGA to 0 or 1 at visit 4 after 14 days treatment | From Visit 2 (Day 1) to Visit 4 (Day 15) (14 days treatment) | Proportion of subjects with the Investigator's Global Assessment (IGA) score of 0 or 1 at Visit 4 (Day 15). |
| Secondary | Efficacy - the change of IGA | Evaluated at Visit 3 (Day 8), Visit 5 (Day 22), and Visit 6 (Day 29) | Proportion of subjects achieving the Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) at Visit 3 (Day 8), Visit 5 (Day 22), and Visit 6 (Day 29) |
| Secondary | Efficacy - the change of lesion area(s) (cm²) | Evaluated at Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 22) and Visit 6 (Day 29) | Change from baseline (Visit 2) of lesion area(s) to Visit 3-6 |
| Secondary | Efficacy - the change of pruritus NRS | Evaluated at Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 22) and Visit 6 (Day 29) | Change from baseline (Visit 2) in pruritus NRS(Numerical Rating Scale) of itch level on lesion area(s) to Visit 3-6 |
| Secondary | Efficacy - the change ≥ 2 points of reduction of pruritus NRS | Evaluated at Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 22) and Visit 6 (Day 29) | Proportion of subjects having ≥ 2 points of reduction from baseline (Visit 2) in pruritus NRS for worst itch in the past 24 hours on lesion area(s) to Visit 3-6 |
| Secondary | Efficacy - the change of signs of atopic dermatitis | Evaluated at Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 22) and Visit 6 (Day 29) | Change from baseline (Visit 2) in signs of atopic dermatitis (erythema, edema/papulation, excoriation, and lichenification) with grading from 0(none) to 3(severe) on lesion area(s) to Visit 3-6 |
| Secondary | Safety- AE and SAE | Evaluated at Visit 2 (Day 1), Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 22) and Visit 6 (Day 29) | Incidence of AE and SAE during Visit 2-6 and AE will be categorized by severity (toxicity grade) and relationship to the study intervention |
| Secondary | Safety - change of vital sign | Evaluated at Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 22) and Visit 6 (Day 29) | Change from baseline (Visit 2) in vital signs to Visit 3-6 |
| Secondary | Safety - abnormality in physical examination occurred | Evaluated at Visit 2 (Day 1), Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 22) and Visit 6 (Day 29) | Abnormality in physical examination at Visit 2-6 |
| Secondary | Safety - ECG result | Evaluated at Visit 2 (Day 1), Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 22) and Visit 6 (Day 29) | Transition of ECG result from normal to abnormal findings from baseline (Visit 2) to Visit 3-6 |
| Secondary | Safety - Lab parameters | Evaluated at Visit 1 (-14 to -1 Day), (Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 22) and Visit 6 (Day 29) | Change from baseline (Visit 1) in laboratory parameters to Visit 3-6 |
| Secondary | Safety - assessment of local tolerability | Evaluated at Visit 2 (Day 1), Visit 3 (Day 8), Visit 4 (Day 15), Visit 5 (Day 22) and Visit 6 (Day 29) | Proportion of subjects with scores of 0 and 1 in each symptom of assessment of local tolerability (erythema, edema, vesiculation, and excoriation) with grading from 0 (none) to 3 (severe) at Visit 2-6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07914088/registered